Hashida Hiroki, Inoue Yoshikage, Hattori Kengo, Kadono Kentaro, Yoshimura Mio, Yoshida Masahiro, Abe Satsuki, Miyake Mafumi, Yoshitomi Mami, Nomura Akinari, Ueda Shugo, Terajima Hiroaki, Osaki Nobuhiro
Dept. of Gastroenterological Surgery and Oncology,Tazuke Kofukai Medical Institute, Kitano Hospital.
Gan To Kagaku Ryoho. 2012 Apr;39(4):637-9.
A 70-year-old female patient underwent pylorus-preserving pancreaticoduodenectomy for carcinoma of the ampulla of Vater in March 2007. In April 2009, multiple lung metastases were detected by CT scanning. The patient was treated with S-1 (80mg/day, day 1-28, followed by 2-weeks withdrawal)from April 2009. The shrinkage of lung metastases was diagnosed as a complete response based on the Response Evaluation Criteria in Solid Tumors(RECIST). No severe toxicities were observed. S-1 is an effective and safe anti-cancer agent available for lung metastases of carcinoma of the ampulla of Vater.
一名70岁女性患者于2007年3月因 Vater壶腹癌接受了保留幽门的胰十二指肠切除术。2009年4月,CT扫描发现多处肺转移。该患者自2009年4月起接受S-1治疗(80mg/天,第1 - 28天,随后停药2周)。根据实体瘤疗效评价标准(RECIST),肺转移灶的缩小被诊断为完全缓解。未观察到严重毒性反应。S-1是一种有效且安全的抗癌药物,可用于治疗 Vater壶腹癌的肺转移。